Document is current
Any future updates will be listed below
-
Authors
Johnson, Matthew G.
Strizki, Julie M.
Brown, Michelle L.
Wan, Hong https://orcid.org/0000-0003-0679-9565
Shamsuddin, Hala H.
Ramgopal, Moti
Florescu, Diana F.
Delobel, Pierre https://orcid.org/0000-0002-2874-3581
Khaertynova, Ilsiyar https://orcid.org/0000-0001-5347-4670
Flores, José F.
Fouche, Leon F.
Chang, Shan-Chwen
Williams-Diaz, Angela
Du, Jiejun
Grobler, Jay A.
Paschke, Amanda
De Anda, Carisa
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04575597 at ClinicalTrials.govDocuments that mention this clinical trial
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
https://doi.org/10.1007/s15010-022-01959-9
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
https://doi.org/10.1007/s40121-023-00891-1
- License Information
-
More Information
Article History
Received: 28 September 2022
Accepted: 11 November 2022
First Online: 17 January 2023
Declarations
:
: Matthew G. Johnson, Julie M. Strizki, Michelle L. Brown, Hong Wan (at the time of study), Hala H. Shamsuddin, Angela Williams-Diaz, Jiejun Du (at the time of study), Jay A. Grobler, Amanda Paschke, and Carisa De Anda are employees of Merck & Co., Inc., Rahway, NJ, USA. Moti Ramgopal: Consulting fees: Gilead, Merck, ViiV, Janssen; Honoraria: Gilead, ViiV, Janssen. Diana F. Florescu: Grants: Merck, Regeneron, Astellas, Novavax, Bavarian Nordic, Takeda, SymBio, NobelPharma, AlloVir. Consulting fees: Takeda and Merck; Data Safety Monitoring Board/Advisory Board: Medpace. Pierre Delobel: Travel grants: BMS, Gilead, MSD, and Janssen in the last 5 years; Society: HAS/ANRS-MIE/CNS: French recommendations for treatment and prevention of HIV, hepatitis, and STIs; Scientific Committee: ANRS-MIE (CSS13). Ilsiyar Khaertynova: Nothing to disclose. José F. Flores: Nothing to disclose. Leon F. Fouche: Nothing to disclose. Shan-Chwen Chang: Nothing to disclose.
